E2E Project Control Lead
About the job
- A Master of Science, Bachelor of Science, or diploma in Engineering, Accounting, or Business Administration is required; an additional degree in Construction Management is a plus.
- Significant experience in project control is required.
- Demonstrated experience in estimating, cost management, forecasting, and progress measurement is required.
- Significant experience in contract and risk management is required.
- Experience and strong analytical skills in cost estimating, cash flow and forecasting, change orders, and value analysis are required.
- Fluency in German and English is required.
- Develop and manage a team to deliver the project.
- Deliver the End to End Frankfurt project, including a schedule with resource loading.
- Implement Earned Value Measurement tracking tools, conduct float analysis, and develop early/late progress curves.
- Lead development and management of an accurate cost forecast for the project, including planned spend and invoicing with payment terms versus actuals and commitments, and planned/placed purchase orders versus actuals.
- Support management, forecasting, reporting, and control of Project Change Management for engineering and construction changes.
- Support the project control team in risk assessment, manage the risk register, and determine and appropriately use the risk and contingency allowances required to complete the project.
- Manage and support timely preparation of weekly and monthly status reports and Steering Committee preparation.
- Additional languages are welcome.
About the company
Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Get referred to Sanofi
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
- June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
- Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.
What critics are saying
- Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
- Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
- Dupixent concentration makes 2030s patent loss an existential revenue shock.
What makes Sanofi unique
- Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
- October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
- Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Professional Development Budget
- Parental Leave